Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference

Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present on the company’s proprietary therapeutic technology indicated for the treatment of diseases that affect the central nervous system, such as amyotrophic lateral sclerosis (ALS).

Neuralstem has developed a technology that allows the production of neural stem cells in regionally specific and physiologically pertinent locations, making it a novel therapeutic option for patients who suffer from diseases of the central nervous system. This technology’s development led to the discovery of a series of already-patented small molecule neurogenic compounds that the company expects to offer as treatment for psychological and cognitive conditions.

The company is currently investigating its first stem cell therapy product, which is a spinal cord-derived neural stem cell line called NSI-566. The product is still undergoing clinical trials for its application in ALS. It has also been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).

Neuralstem previously completed patient dosing under its Phase 2a trial for NSI-566, and is planning on initiating the next trial later this year. In addition, the company is also studying the efficacy of NSI-566 as a treatment for chronic spinal cord injury, which is now in its phase I of clinical development. Studies to evaluate its use in ischemic stroke are also in the works.

The company has dedicated much of its efforts to the discovery and development of small molecule drugs, within a program that screens human neural stem cell lines for compounds thought to be able to stimulate neurogenesis in the brain. Neuralstem has already conducted phase Ia and Ib safety trials to evaluate NSI-189 for major depressive disorder, and is planning to initiate a Phase II trial later this year.

Garr’s presentation will be available via a live audio webcast on the Investor Center home page of the Company’s website, which will remain accessible for a 30-day period.